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Aspirin-induced nuclear translocation of NFkB and apoptosis in
colorectal cancer is independent of p53 status and DNA
mismatch repair proficiency
FVN Din1, LA Stark1 and MG Dunlop*,1
1Colon Cancer Genetics Group, Department of Oncology, Division of Clinical and Molecular Medicine and MRC Human Genetics Unit, Western General
Hospital, University of Edinburgh, Crewe Rd, Edinburgh EH4 2XU, Scotland
Substantial evidence indicates nonsteroidal anti-inflammatory drugs (NSAIDs) protect against colorectal cancer (CRC). However, the
molecular basis for this anti-tumour activity has not been fully elucidated. We previously reported that aspirin induces signal-specific
IkBa degradation followed by NFkB nuclear translocation in CRC cells, and that this mechanism contributes substantially to aspirin-
induced apoptosis. We have also reported the relative specificity of this aspirin-induced NFkB-dependent apoptotic effect for CRC
cells, in comparison to other cancer cell types. It is now important to establish whether there is heterogeneity within CRC, with
respect to the effects of aspirin on the NFkB pathway and apoptosis. p53 signalling and DNA mismatch repair (MMR) are known to
be deranged in CRC and have been reported as potential molecular targets for the anti-tumour activity of NSAIDs. Furthermore,
both p53 and MMR dysfunction have been shown to confer resistance to chemotherapeutic agents. Here, we set out to determine
the p53 and hMLH1 dependency of the effects of aspirin on NFkB signalling and apoptosis in CRC. We specifically compared the
effects of aspirin treatment on cell viability, apoptosis and NFkB signalling in an HCT-116 CRC cell line with the p53 gene
homozygously disrupted (HCT-116p53/) and an HCT-116 cell line rendered MMR proficient by chromosomal transfer (HCT-
116þ ch3), to the parental HCT-116 CRC cell line. We found that aspirin treatment induced apoptosis following IkBa degradation,
NFkB nuclear translocation and repression of NFkB-driven transcription, irrespective of p53 and DNA MMR status. These findings
are relevant for design of both novel chemopreventative agents and chemoprevention trials in CRC.
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Ingestion of nonsteroidal anti-inflammatory drugs (NSAIDs) has
been shown to be associated with a 40–50% reduction in relative
risk of colorectal cancer (CRC) (Thun et al, 1993). There is much
research effort focussed on the molecular mechanisms involved
in NSAID anti-tumour activity. Such understanding would
inform the rational design of novel agents both for chemopreven-
tion and therapy.
We previously reported the pivotal involvement of the
transcription factor NFkB (p50 –p65) in aspirin-mediated apopto-
sis in CRC cells (Stark et al, 2001). NFkB is sequestered in the
cytoplasm, bound to a member of the IkB family of inhibitory
proteins. Stimulation by one of a range of signals results in
phosphorylation and ubiquitination of IkB followed by proteo-
some-mediated degradation. Dissociation from IkB results in
NFkB nuclear translocation and transcriptional regulation of
numerous target genes. NFkB has been shown to have both pro-
and anti-apoptotic effects (Barkett and Gilmore, 1999). Such
disparate effects are due to differences in stimuli, NFkB composi-
tion, cell type and distinct kB binding specificities of individual
complexes resulting in diverse target gene specificity (Epinat and
Gilmore, 1999). We have previously shown that aspirin-mediated
apoptosis in CRC cells involves IkBa degradation and NFkB
nuclear translocation (Stark et al, 2001). We also demonstrated
that aspirin-induced IkBa degradation was required for apoptosis
because cells constitutively expressing super-repressor IkBa were
resistant to both aspirin-induced NFkB nuclear translocation and
apoptosis. More recently, we have reported the relative specificity
of this NFkB-dependent apoptotic effect of aspirin for CRC cells,
when compared to other cancer cell types (Din et al, 2004).
However, it is also important to determine whether there is
heterogeneity within CRC, with respect to the effects of aspirin on
the NFkB pathway and apoptosis.
It is now well established that genomic instability, by increasing
mutational load, promotes neoplastic progression in CRC. The p53
tumour suppressor gene is involved in cell cycle control, apoptosis
and maintenance of genomic stability and is frequently mutated in
colorectal tumours, heralding malignant transformation (Baker
et al, 1989, 1990; Honma et al, 2000). Another important
contributor to genomic instability is defective DNA mismatch
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repair (MMR) resulting in microsatellite instability (MSI) (Veigl
et al, 1998). MSI is the hallmark of tumours arising in hereditary
nonpolyposis colorectal cancer (HNPCC) and is also found in 15%
of sporadic CRCs (Boland et al, 1998; Brown et al, 1998). The
majority of MSI tumours in familial cases are due to germline
mutations in hMLH1, hMLH2 and hMSH6 genes, and to hMLH1
promoter hypermethylation in sporadic cancers (Kuismanen et al,
2000). p53 dysfunction and DNA MMR deficiency are almost
wholly mutually exclusive (Cottu et al, 1996; Samowitz et al, 2001).
p53 signalling and DNA MMR have been identified as potential
molecular targets for NSAIDs (Ruschoff et al, 1998; Shao et al,
2000; Goel et al, 2003), suggesting that the anti-tumour effect may,
in part, involve countering the effects of genetic instability in CRC.
Such genetic aberrations in tumours have also been shown to be
involved in determining response to chemotherapeutic agents
(O’Connor et al, 1997; Weller, 1998; Ribic et al, 2003).
In light of the importance of p53 and MMR in CRC and that
genomic instability can influence response to chemotherapeutics,
we set out to determine the p53 and hMLH1 dependency of the
effects of aspirin on NFkB signalling. Our findings suggest that the
NFkB-apoptotic response to aspirin occurs irrespective of p53
status and MMR defects and shed further light on the chemopre-
ventive action of NSAIDs.
MATERIALS AND METHODS
Cell line culture and treatment
The CRC cell line HCT-116 (genotype p53 (þ /þ ), hMLH1 ()), is
available from the American Type Culture Collection (ATCC). The
HCT-116 cell line has a hemizygous mutation in hMLH1 resulting
in a truncated, nonfunctional protein. The HCT-116 subline where
hMLH1 expression is restored by chromosome 3 transfer
(HCT116þ ch3, genotype p53 (þ /þ ), hMLH1 (þ )) was a gift
from Professor CR Boland and these cells are competent in DNA
MMR (Koi et al, 1994). The p53 null HCT-116 subline (HCT-
116p53/) was created by targeted homologous recombination
(Bunz et al, 1999) and was a gift from Professor B Vogelstein. All
three cell lines were grown in McCoy’s 5A media and the HCT-
116þ ch3 cell line was grown under selection with 0.4 mg ml1
geneticin. All media were supplemented with 10% foetal calf serum
(FCS) and 1% penicillin/streptomycin (media supplied by Gibco
BRL, Paisley, UK) and cells were grown as monolayers (371C in 5%
CO2). Cells were plated (1 106 cells/50 ml flask) and grown until
60–70% confluent. Aspirin (Sigma, St Louis, USA) was prepared as
a 0.5 M stock solution in distilled water (final pH 7.0). Prior to
treatment for 16 h with aspirin (1, 3, 5 and 10 mM) or carrier
control (at same concentrations as aspirin), the growth medium
was replaced with the respective low serum (0.5% FCS) medium.
Cell viability and determination of apoptosis
After aspirin treatment, adherent cells were harvested and viable
cell number determined by counting with a haemocytometer. Cell
surface phosphatidylserine is a marker for apoptosis and was
detected via its interaction with annexin V using the Annexin V-
FITC apoptosis detection kit (Oncogene Research Products,
Cambridge, MA, USA), as per the manufacturer’s instructions.
Briefly, the media from the flask of adherent cells was transferred
to a conical tube on ice to harvest any floating cells. Cells were then
washed with 2 ml of PBS, which was also added to the tube to
collect any cells dislodged during washing. Cells were incubated
with 1 ml of trypsin : versene (volume per volume) just until the
cells detached and then resuspended in the conical tube containing
the media with the floating and washed cells. Cells were counted
using a haemocytometer and resuspended in cold 1 binding
buffer to approximately 1 106 cells ml1. Media binding reagent
(10ml) was added to 0.5 ml of the cell suspension, which was
incubated with 1.25ml of annexin V-FITC for 15 min at room
temperature in the dark. Annexin V was then removed by
centrifugation at 1000 g for 5 min and the cells were resuspended
in 0.5 ml of cold 1 binding buffer and placed on ice. The
counting was carried out using a haemocytometer (two counting
grids) in duplicate and this was carried out immediately following
staining of cells as apoptosis is an ongoing process and the FITC
signal may be lost after an hour.
Western blotting
After aspirin treatment, cells were washed with PBS, centrifuged
(1200 r.p.m. for 10 min) and cell pellets were resuspended in lysis
buffer (50 mM NCl, 10 mM HEPES, 500 mM sucrose, 1 mM EDTA,
0.5 mM. spermidine, 0.15 mM spermine, 0.2% Triton X-100,
Complete Protease Inhibitor Cocktail (Roche Diagnostics, Man-
heim, Germany), 100 mM Pefabloc (Roche Diagnostics, Manheim,
Germany)). The cell suspension was centrifuged (6000 r.p.m. for
15 min, 41C) and the supernatant used as cytoplasmic extract.
Protein content was measured by the method of Bradford (BioRad,
Hercules, CA, USA).
Cytoplasmic proteins (30mg) were separated on a 10% SDS–
PAGE gel, transferred to a polyvinylidine difluoride membrane
(BioRad) and blocked in 4% non-fat dry milk solution with 0.3%
Tween20 (Sigma). Membranes were probed with a sheep
polyclonal IkBa antibody (a gift from Professor R Hay, University
of St Andrews, UK) and then with monoclonal antibody to
Cu/Zn SOD (The Binding Site, Birmingham, UK) as a control for
protein loading. Chemiluminescence was used to visualise the
antigen–antibody complexes (Amersham ECL Reagents, Little
Chalfont, UK).
Electrophoretic mobility shift assays
Electrophoretic mobility shift assays were carried out by incubat-
ing nuclear extracts from untreated cells (6mg) with binding
reaction mix (1 binding buffer (50 mM KCl, 20 mM HEPES, 5%
glycerol, 1 mM EDTA, 1 mM DTT), 1 mg BSA, 1 mg poly dI-dC,
25 fmol radioactively labelled oligo-DNA in a final volume of 20 ml)
for 30 min prior to analyses on a 4% native polyacrylamide gel.
Double-stranded oligonucleotides for NFkB were obtained from
Santa Cruz.
Immunofluorescence analysis
Cells grown to 60–70% confluence on glass coverslips were treated
with carrier or 10 mM aspirin for 16 h (in respective 0.5% FCS
medium). After treatment, cells were washed with PBS, fixed with
acetone : methanol (volume per volume) (201C, 10 min) and
blocked in 10% nonimmune donkey serum (Sigma) for 1 h. Rabbit
polyclonal antibody to NFkB p65 (Santa Cruz) was applied for 1 h
followed by incubation with FITC-conjugated donkey anti-rabbit
IgG for 1 h. The nuclei were stained with DAPI and the coverslips
mounted with Vectashield (Vector Laboratories, Burlingame,
California, USA).
Transfections and reporter assays
For transient transfection experiments, 50 ml flasks of cells were
grown to subconfluency then transfected with 6 mg of luciferase
reporter plasmid and 3 mg of b-galactosidase control plasmid,
using Lipofectamine as described by the manufacturer’s instruc-
tions (Gibco BRL). Following transfection, cells were grown in low
serum (0.5% FCS) medium then treated with aspirin (0–10 mM)
for 16 h. Luciferase activity was measured in cell extracts using a
luciferase reporter assay kit (Promega) and read using a
luminometer. Transfection efficiency and cell viability were
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monitored by cotransfection with a CMV-b-galactosidase reporter
plasmid and b-galactosidase activity was quantified with an assay
kit (Promega), as per the manufacturer’s instructions. Relative
luciferase activity was calculated as unit of luciferase activity per
unit of b-galactosidase activity.
RESULTS
Basal expression of IjBa and p65 proteins in CRC cell lines
is independent of p53 and hMLH1 expression
To investigate the relationship between p53 and MMR status and
the NFkB-dependent apoptotic response to aspirin, we used the
following three CRC cell lines: parental HCT-116 cells (wild-type
p53, hMLH1 deficient), HCT-116þ ch3 (wild-type p53, hMLH1
proficient) and HCT-116p53/ (p53 null, hMLH1 deficient). The
presence of hMLH1 in the HCT-116þ ch3 cell line and the absence
of p53 in the HCT-116p53/ cell line was verified by immunoblot
analysis (Figure 1A). Firstly, we considered whether p53 and
hMLH1 mutation status might affect basal levels of IkBa and p65
proteins. Using immunoblot analysis of cytoplasmic extracts, we
found there were no significant differences in expression of IkBa
or p65, or their relative levels (data not shown), between the three
CRC cell lines (Figure 1B). These results indicate that changes in
MMR mutation status and p53 expression do not affect the
cytoplasmic pool of either protein available for stimulation. We
next considered whether basal levels of NFkB DNA binding were
affected by changes in p53 or MMR status. Electrophoretic
mobility shift assays (EMSAs) performed on nuclear extracts of
untreated cells showed basal NFkB DNA binding in the three CRC
cell lines (Figure 1C). The differences in basal levels of NFkB DNA
binding complexes in the HCT-116þ ch3 and HCT-116p53/ cell
lines compared to the parental HCT-116 cell line were marginal
(densitometry data not shown).
Aspirin induces apoptosis in CRC cell lines independent of
p53 and MMR status
To determine whether p53 and MMR status affects the aspirin-
mediated reduction in cell viability we have previously observed,
we compared the effects of aspirin treatment on the viability of
HCT-116þ ch3 and HCT-116p53/ cell lines to the parental HCT-
116 cell line. In triplicate dose– response experiments, all CRC cell
lines were treated for 16 h with aspirin (1, 3, 5 and 10 mM) and
viable cell number determined by haemocytometric counts.
Aspirin treatment resulted in a concentration-dependent decrease
in the number of viable cells in all three CRC cell lines (Figure 2A).
Furthermore, the cell lines showed proportionate decreases in cell
viability at each concentration increment, indicating a similar
sensitivity to aspirin, irrespective of p53 or MMR status
(Figure 2B). The IC50 values were calculated from the growth
curves of the aspirin-treated CRC cell lines (Table 1) and there
were no significant differences in levels of cell death with each
genetic background.
It is well established that aspirin induces apoptosis in CRC cell
lines (Piazza et al, 1995; Qiao et al, 1998; Stark et al, 2001; Din et al,
2004). We next confirmed that the reduction in viable cell number
in each of the cell lines was indeed due to apoptosis for all three
genotypes, and not simply a growth inhibitory effect. Following
aspirin treatment, cells were stained with Annexin V, which binds
phosphatidylserine residues that are externalised during apoptosis
and thus serves as a marker for programmed cell death. Consistent
with the reduction in cell viability, we found that aspirin induced a
concentration-dependent increase in the proportion of apoptotic
cells in all three CRC cell lines (Figure 2C). Furthermore, there was
no significant difference in apoptotic response between any of the
HCT-116, HCT-116þ ch3 and HCT-116p53/ cell lines. In addition
there was good correlation between the IC50 value and apoptotic
response; the lower the IC50 value, indicating greater sensitivity at
a lower aspirin concentration, the greater the fold increase in
apoptosis (r¼0.98). These data suggest that aspirin-mediated
apoptosis in CRC cells is independent of p53 and MMR status.
Aspirin induces IjBa degradation and NFjB nuclear
translocation in CRC cell lines irrespective of p53 and
MMR status
Having shown previously that p65 nuclear translocation is a
critical event in effecting the apoptotic response to aspirin (Stark
et al, 2001), we next studied the effect of aspirin on NFkB
signalling in each cell line. Since IkBa sequesters NFkB in the
cytoplasm, we first investigated the effect of aspirin treatment on
the cytoplasmic levels of IkBa in each cell line using immunoblot
analysis. We found that aspirin treatment induced degradation of
IkBa in a similar concentration-dependent manner in each cell line
genotype (Figure 3A). We next determined whether the IkBa
degradation was accompanied by NFkB nuclear translocation in
the CRC cell lines. Immunofluorescence analysis showed that
following 16 h aspirin exposure, p65 translocated from the
cytoplasm to the nucleus in each cell line, irrespective of p53
and MMR status (Figure 3B). These findings indicate that aspirin-
induced apoptosis, due to modulation of the NFkB pathway,
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Figure 1 Basal expression of p53, hMLH1, IkBa and p65 in untreated
colorectal cancer cell lines. Cytoplasmic extracts were made from
untreated cells and Western blots probed with p53 and hMLH1 antibodies
to confirm the expression profile of the cell lines (A). Cytoplasmic extracts
were probed with sheep polyclonal IkBa and rabbit polyclonal p65
antibodies to examine the basal expression of proteins in the cell lines (B).
The Western blots shown are representative of at least three independent
experiments and Cu/Zn SOD was used as a control for protein loading.
Electrophoretic mobility shift assay using NFkB consensus oligonucleotide,
performed on nuclear extracts of untreated cells, demonstrated basal
NFkB DNA binding activity (C).
Aspirin effects on NFjB and apoptosis in colon cancer cells
FVN Din et al
1139
British Journal of Cancer (2005) 92(6), 1137 – 1143& 2005 Cancer Research UK
G
e
n
e
ti
c
s
a
n
d
G
e
n
o
m
ic
s
occurs irrespective of derangements in p53 signalling and the
MMR system.
Aspirin-mediated repression of NFjB-driven reporter
activity is unrelated to p53 and MMR status
We have previously demonstrated aspirin-induced nuclear trans-
location of NFkB results in repression of NFkB transcriptional
activity in CRC cell lines (Stark et al, 2000). This was recently
substantiated by the finding that NFkB induced by some cytotoxic
stimuli acts as an active repressor of anti-apoptotic gene
expression (Campbell et al, 2004). The effect of aspirin on
NFkB-driven transcription was investigated to determine whether
p53 or MMR mutation status affects the ability of aspirin to induce
NFkB transcriptional repression in CRC cells. The cell lines were
transiently transfected with the 3enhancer-ConA NFkB-dependent
luciferase reporter construct in which transcription of the firefly
luciferase gene is driven by three kB binding sites (Roff et al,
1996). A reporter plasmid with deleted kB sites served as control.
Following transfection, cells were exposed to aspirin for 16 h.
There was a substantial decrease in the basal levels of NFkB-driven
reporter activity following aspirin exposure and this was observed
in a concentration-dependent manner, irrespective of p53 or MMR
status (Figure 4). These findings show that aspirin-induced
repression of NFkB transcriptional activity, and hence downstream
regulation of target genes, is independent of p53 signalling and
DNA MMR.
DISCUSSION
We previously reported that the effects of aspirin on NFkB
signalling are a centrally important mechanism of aspirin-
mediated apoptosis in CRC cells (Stark et al, 2001; Din et al,
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Figure 2 Effect of aspirin on cell viability and apoptosis in colorectal cancer (CRC) cell lines. Aspirin treatment (0–10 mM) for 16 h induces a
concentration-dependent decrease in viable cell number (determined by haemocytometric counts) in all CRC cell lines (A). The decrease in cell viability is
proportionate at each concentration increment indicating a similar pattern of response following aspirin treatment in each cell line (B). Annexin V binding
assay used to determine that all CRC cell lines undergo apoptosis after aspirin treatment (0–5 mM) (C). The graphs represent three independent
experiments and the bars on the graphs are standard error bars.
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2004). This work considerably extends these previous observations
since we have shown that the effect of aspirin on apoptosis and
NFkB signalling is independent of p53 and DNA MMR status.
Furthermore, we show that aspirin induces nuclear translocation
of p65 that is associated with repression of kB-driven transcrip-
tion, again independent of p53 or MMR status.
It is well established that aspirin has a chemopreventive effect
in CRC, but the mechanism of action has not been fully
characterised. It is apparent that inhibition of the cyclo-
oxygenase-2 enzyme (COX-2) plays a part in the anti-tumour
effect of NSAIDs in CRC (Marnett and DuBois, 2002). However, it
is also clear that there are other important mechanisms involved
since the growth inhibitory and apoptotic effects of NSAIDs occur
in CRC cell lines that do not express COX-2 (Hanif et al, 1996;
Elder et al, 1997). Furthermore, NSAIDs that lack COX-2 activity
are growth inhibitory and also induce apoptosis in CRC cells
(Piazza et al, 1995, 1997; Elder et al, 1997). It has also been
shown that NSAID concentrations required for growth inhibi-
tion differ from those for COX-2 enzyme inhibition (Charalam-
bous and O’Brien, 1996; Hanif et al, 1996). Taken together, such
evidence indicates that while COX-2 inhibition is important,
there are other essential mechanism(s) of action. p53 function and
DNA MMR have been proposed as potential targets responsible for
the anti-tumorigenic properties of NSAIDs (Ruschoff et al, 1998;
Shao et al, 2000).
The p53 signalling pathway is central to regulating cell growth
and death, and stabilisation of p53 by mutation is a key event
occurring late in colorectal tumorigenesis (Baker et al, 1990).
Several studies have shown an association between p53 mutation
status and sensitivity to chemotherapeutic drugs in colorectal and
other cancers (O’Connor et al, 1997; Weller, 1998). The p53
pathway has been postulated as a potential target since NSAIDs
have been shown to alter levels of p53 (Goldberg et al, 1996; Kralj
et al, 2001). Furthermore, there is evidence for regulatory
interdependence between p53 and NFkB involving competition
for common coactivators (Wu and Lozano, 1994; Webster and
Perkins, 1999). Indeed, wild-type p53 has been shown to suppress
constitutive NFkB activity and lead to apoptosis (Shao et al, 2000),
suggesting that tumours expressing wild-type p53 may be more
susceptible to aspirin-induced apoptosis.
Our previous work indicated that CRC cell lines expressing wild-
type p53 were not more sensitive to aspirin-induced apoptosis
mediated by NFkB signalling, but there are differences other than
p53 status between the cell lines studied (Din et al, 2004). In
this study, we specifically investigated the effects of p53 on the
NFkB-induced apoptotic response by use of HCT-116 cells with
the p53 gene homozygously disrupted by targeted homologous
recombination (Bunz et al, 1999). Using this approach, we have
shown that aspirin-induced apoptosis is independent of p53 in
CRC cells. Furthermore, p53 does not appear to play a role in
aspirin-induced effects on NFkB signalling or on the repression of
NFkB transcriptional activity. These findings are important in
terms of chemoprevention since p53 mutant CRCs have
been shown to differ in behaviour from those expressing
wild-type p53, with respect to response to chemotherapeutic
agents and prognosis.
Defective DNA MMR is characteristic of HNPCC and around
15% of sporadic CRCs also exhibit genetic instability, mainly due
to epigenetic silencing of hMLH1 but also to somatic MMR gene
defects (Herman et al, 1998). The DNA MMR system has been
implicated as a potential pathway for modulation that may
contribute to NSAID anti-tumour activity (Ruschoff et al, 1998;
Goel et al, 2003). Our previous work suggested that MMR
proficient cells may be more sensitive to aspirin-induced apoptosis
since the MMR-deficient cell lines had greater IC50 values than
MMR-proficient cell lines (Din et al, 2004). Hence, we examined
whether MMR status influenced NFkB-dependent aspirin-induced
apoptosis, by comparing the MMR-deficient HCT-116 to its
proficient counterpart HCT116þ ch3. We observed a dose-depen-
dent increase in apoptosis after treatment with aspirin following
IkBa degradation, NFkB nuclear translocation and repression
of NFkB-driven transcription in both cell lines. The parental
HCT-116 cells, which are MMR deficient, did appear to have a
marginally lower IC50 value and show a greater fold increase
in apoptosis when compared to the MMR-proficient cell line,
but this was not significant (Table 1). Although we did not
detect any significant differences in the NFkB-dependent
apoptotic response to aspirin attributable to MMR status,
long-term in vitro aspirin exposure has been shown to select for
microsatellite stability in colorectal and gastric cancer cell lines
(Ruschoff et al, 1998; Yamamoto et al, 1999). It has also recently
been shown that aspirin treatment increased MMR protein
expression and apoptosis in CRC cell lines (Goel et al, 2003).
However, we found no evidence that MMR status influences the
NFkB-dependent apoptotic response, suggesting that the MMR
system is not the predominant pathway responsible for NSAID
anti-tumour activity.
HCT-116 HCT-116+ch3 HCT-116p53−/−
HCT-116 HCT-116+ch3 HCT-116p53−/−
IB
CuZnSOD
0 1 3 5 10
mM aspirin
0 1 3 5 10
mM aspirin
0 1 3 5 10
mM aspirin
Untreated
Treated
A
B
Figure 3 Aspirin induces IkBa degradation and nuclear translocation of
p65 in colorectal cancer (CRC) lines. Following aspirin treatment,
cytoplasmic extracts were made from untreated and treated cells and
probed with sheep polyclonal IkBa antibody. Western blot analysis shows
that aspirin treatment (0–10 mM) for 16 h induces IkBa degradation in a
concentration-dependent manner in the HCT-116, HCT116þ ch3 and
HCT-116p53/ CRC cell lines (A). The Western blot shown is
representative of at least three independent experiments and Cu/Zn
SOD was used as a control for protein loading. Micrographs (63 ) of
immunocytochemically stained cells show that aspirin treatment (10 mM)
for 16 h induces nuclear accumulation of p65 in the HCT-116,
HCT116þ ch3 and HCT-116p53/ CRC cell lines (B).
Table 1 IC50 values for colorectal cancer cell lines
Fold increase apoptosis
CRC cell line IC50 3 mM 5 mM
HCT-116 2.8 2.3 3.1
HCT-116+ch3 3.1 2.4 2.6
HCT-116p53/ 4.3 1.5 1.8
Cells were treated with aspirin (1,3,5,10 mM) for 16 h and cell numbers determined as
described in Materials and Methods. There is an inverse correlation between IC50
values and the fold increase in apoptosis at both 3 and 5 mM (r¼0.93 and 0.98).
Results are mean of at least three different experiments.
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This work consolidates our previous findings that aspirin-
induced apoptosis occurs after IkB degradation, NFkB nuclear
translocation and repression of NFkB-driven transcription. The
results presented here shed further light on the complex
mechanisms by which NSAIDs induce cell death in CRC.
Elucidation of the mechanism lies in defining the relative
contribution of putative targets to aspirin’s anti-tumour activity.
We found no evidence for the involvement of p53 or DNA MMR
on inducing the NFkB pathway, nor on the ensuing apoptotic
response. Genomic instability due to p53 or MMR dysfunction has
been to shown to be associated with resistance to chemother-
apeutic agents. Hence, these findings may inform rational design
of novel therapeutics. In addition, since aspirin effects on NFkB
and apoptosis occur in cancers arising from different genetic
backgrounds, these findings are clinically relevant when consider-
ing design of chemoprevention trials, both in genetically predis-
posed individuals with defective MMR and in low and moderate
risk populations, since p53 mutational events are important during
development and progression of colorectal neoplasia.
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